Skip to main
TXG

10X Genomics (TXG) Stock Forecast & Price Target

10X Genomics (TXG) Analyst Ratings

Based on 12 analyst ratings
Hold
Strong Buy 17%
Buy 17%
Hold 67%
Sell 0%
Strong Sell 0%

Bulls say

10x Genomics is in a strong financial position with a high cash balance and low debt, allowing for potential investments in future growth opportunities. Although recent production results were below expectations, the company's long-term outlook remains positive with a strong pipeline of products and solutions in the life science technology industry. Additionally, their acquisition of Prime Mining in 2025 has added further growth potential to their portfolio.

Bears say

10x Genomics is currently experiencing business growth and has released a positive Los Reyes PEA, but Q2 production results show that this growth may be skewed towards the second half of 2026. While the PEA delivered a strong after-tax NPV and IRR, the upfront capex of US$515M and LOM production and AISC figures may be concerning and could impact the company's financials in the long term.

10X Genomics (TXG) has been analyzed by 12 analysts, with a consensus rating of Hold. 17% of analysts recommend a Strong Buy, 17% recommend Buy, 67% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of 10X Genomics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About 10X Genomics (TXG) Forecast

Analysts have given 10X Genomics (TXG) a Hold based on their latest research and market trends.

According to 12 analysts, 10X Genomics (TXG) has a Hold consensus rating as of Aug 29, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $38, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $38, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

10X Genomics (TXG)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.